An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

• Status: Withdrawn
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mereo BioPharma
• Collaborator: ICON Clinical Research

Criteria

Inclusion Criteria:

• Patients with a clinical diagnosis of OI Type I, III or IV

• Capable of giving signed consent

Exclusion Criteria:

• History of skeletal malignancies or other bone diseases (other than OI)

• History of endocrine or thyroid/parathyroid conditions that could affect bone metabolism

• Treatment with bisphosphonates within 3 months of randomisation

• Treatment with teraparatide, denosomab or other anabolic/antiresorbative medications within 6 months of randomisation